Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Miles....
8
Jul 07, 2010 01:17AM

that might actually be attractive to investors if the dividend payout is high enough

Unfortunately, this proposition is speculative as to revenue potential and the effect of an ever decreasing set of licensees, notwithstanding the acknowledged expiry of the respective patents.

For example, if PTSC has cash reserves of $200million, the share price would rise to reflect that cash position. The price would further rise with the announcement of dividends. With each qualifying date for receipt of a dividend, and subsequent payment, the share price would fall, with the cycle repeating itself until all MMP Portfolio income was exhausted. While this might be attractive to traders, I fail to see how this increases shareholder value.

With no further MMP Portfolio revenues, a zero cash balance, and share price languishing who knows where, this would be an outright dereliction of duty by the BoD, which, as you have frequently stated, should be to grow shareholder value, not run it into the ground.

This brings us to M&A which I shall discuss later, as I have a prior appointment to attend.

.

.

.

Be well

9
Jul 07, 2010 09:19AM
6
Jul 07, 2010 10:31AM
7
Jul 07, 2010 12:55PM
4
Jul 07, 2010 01:59PM
9
Jul 07, 2010 05:06PM
15
Jul 07, 2010 05:50PM
9
Jul 07, 2010 06:06PM

Jul 07, 2010 06:58PM
11
Jul 07, 2010 07:10PM
3
Jul 07, 2010 07:20PM
9
Jul 07, 2010 07:45PM
8
Jul 07, 2010 08:08PM
2
Jul 07, 2010 08:34PM
8
Jul 07, 2010 10:00PM
3
Jul 08, 2010 11:05AM
9
Jul 08, 2010 12:14PM
Share
New Message
Please login to post a reply